Bank of New York Mellon Corp and Massachusetts Financial Services Co. MA are among financial groups that reduced their shares in Labcorp Holdings. Despite this, the company has attracted new investments from Sector Gamma AS and Sivik Global Healthcare LLC. Labcorp's amplification in MRD cancer testing has drawn attention to the company's valuation and was followed by a 10.5% three-month share price decline. 2025 quarter results from Labcorp have been announced along with a quarterly dividend of $0.72. Labcorp's effort to develop its oncology division is noteworthy, as this strategy could redefine its innovation story. The ratings from brokerages suggest a 'Moderate Buy' consensus. Labcorp's addition of Victor Bulto to its Board of Directors indicates a strategic push towards leadership strengthening. Upcoming Q4 financial results, alongside recent financial performance evidence a strong business entity, especially with a positive earnings turnaround narrative. The launch of an FDA-cleared Alzheimer's diagnostic blood test signals Labcorp's firm rootedness in pathbreaking healthcare technology. Furthermore, the acquisition of select assets of BioReference Health's Innovative Oncology and related clinical testing services businesses signifies an expansion in its oncology space.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 11 Mar 2025 07:00:00 GMT to Thu, 29 Jan 2026 10:04:06 GMT -
Rating 3
- Innovation 6
- Information 8
- Rumor 2
